Literature DB >> 32940080

Galectin-3 and acute heart failure: genetic polymorphisms, plasma level, myocardial fibrosis and 1-year outcomes.

Hao Fu1, Shaoping Nie1, Ping Luo1, Yang Ruan2, Zichuan Zhang3, Huangtai Miao1, Xin Li3, Songnan Wen3, Rong Bai3,4.   

Abstract

Aim: This study sought to investigate the relationship between galectin-3 (Gal-3), myocardial fibrosis (MF) and outcomes in acute heart failure. Materials & methods: The single-nucleotide polymorphisms (SNPs) of LGALS3 at rs4644 and rs4652, plasma Gal-3 level, MF and major adverse events (MAEs) were obtained.
Results: There was no significant difference in MAEs when categorizing patients by the LGALS3 SNPs at rs4644 and rs4652. The circulating Gal-3 was related to the degree of MF (p < 0.001). Plasma Gal-3 level and MF can predict an increased risk of MAEs (p < 0.001, p = 0.023, respectively).
Conclusion: Not the SNPs of LGALS3 but Gal-3 and MF can predict MAEs in acute heart failure at 1 year of follow-up.

Entities:  

Keywords:  acute heart failure; galectin-3; major adverse event; myocardial fibrosis; polymorphism

Year:  2020        PMID: 32940080     DOI: 10.2217/bmm-2020-0269

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

1.  Galectin 3 (LGALS3) Gene Polymorphisms Are Associated with Biochemical Parameters and Primary Disease in Patients with End-Stage Renal Disease in Serbian Population.

Authors:  Zoran Kovacevic; Tatjana Lazarevic; Nela Maksimovic; Milka Grk; Vladislav Volarevic; Marina Gazdic Jankovic; Svetlana Djukic; Katarina Janicijevic; Marina Miletic Kovacevic; Biljana Ljujic
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

2.  Galectin-3 for prediction of cardiac function compared to NT-proBNP in individuals with prediabetes and type 2 diabetes mellitus.

Authors:  Volker H Schmitt; Jürgen H Prochaska; Annegret S Föll; Andreas Schulz; Karsten Keller; Omar Hahad; Thomas Koeck; Sven-Oliver Tröbs; Steffen Rapp; Manfred Beutel; Norbert Pfeiffer; Konstantin Strauch; Karl J Lackner; Thomas Münzel; Philipp S Wild
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.